{"nctId":"NCT01777191","briefTitle":"Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis","startDateStruct":{"date":"2013-03"},"conditions":["Plaque Psoriasis"],"count":204,"armGroups":[{"label":"80 mg Ixekizumab Auto-Injector","type":"EXPERIMENTAL","interventionNames":["Drug: Ixekizumab Auto-Injector"]},{"label":"80 mg Ixekizumab Prefilled Syringe","type":"EXPERIMENTAL","interventionNames":["Drug: Ixekizumab Prefilled Syringe"]}],"interventions":[{"name":"Ixekizumab Auto-Injector","otherNames":["LY2439821"]},{"name":"Ixekizumab Prefilled Syringe","otherNames":["LY2439821"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to randomization\n* At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization\n* Static Physician Global Assessment (sPGA) score of at least 3 AND Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization\n* Candidate for phototherapy and/or systemic therapy\n* Men must agree to use a reliable method of birth control during the study\n* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment\n\nExclusion Criteria:\n\n* Pustular, erythrodermic, and/or guttate forms of psoriasis\n* History of drug-induced psoriasis\n* Clinically significant flare of psoriasis during the 12 weeks prior to randomization\n* Concurrent or recent use of any biologic agent\n* Received systemic psoriasis therapy \\[such as psoralen and ultraviolet A (PUVA) light therapy\\] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization\n* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study\n* Have participated in any study with interleukin-17 (IL-17) antagonists, including Ixekizumab\n* Serious disorder or illness other than plaque psoriasis\n* Serious infection within the last 3 months\n* Breastfeeding or nursing (lactating) women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device","description":"Cmax by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"14.8","spread":null}]}]}]},{"type":"PRIMARY","title":"PK: Area Under the Concentration Time Curve From Time Zero to Last Measured Concentration Value (AUC 0-[Tlast]) by Drug Delivery Device","description":"AUC 0-tlast by drug delivery device (prefilled syringe or auto-injector) of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"154","spread":null}]}]}]},{"type":"SECONDARY","title":"PK: Cmax of Ixekizumab by Site of Injection (Arm, Thigh or Abdomen)","description":"Cmax by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]}]},{"type":"SECONDARY","title":"PK: AUC 0-tlast by Site of Injection (Arm, Thigh or Abdomen)","description":"AUC 0-tlast by site of injection of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"178","spread":null}]}]}]},{"type":"SECONDARY","title":"PK: Cmax by Body Weight","description":"Cmax by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. Body weight is defined by (Low: \\<80 kilogram (kg), Medium: 80-100 kg, or High: \\>100 kg).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"PK: AUC 0-tlast by Body Weight","description":"AUC 0-tlast by body weight of Ixekizumab, after the 160 mg starting dose was administered on Day 0. AUC 0-tlast is equal to AUC 0-14 days where the last time point was 14 days ± 24 hours. Body weight is defined by (Low: \\<80 kg, Medium: 80-100 kg, or High: \\>100 kg).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"193","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a ≥75%, ≥ 90% and 100% Improvement in Psoriasis Area and Severity Index (PASI): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index (PASI)","description":"PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease. Participants achieving PASI 75, 90, or 100 are defined as having an improvement of at least 75%, 90%, or of 100%, respectively, in the PASI scores compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null},{"groupId":"OG001","value":"62.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null},{"groupId":"OG001","value":"42.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1): Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment (sPGA)","description":"The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of \"0\" or \"1\" with at least a 2-point improvement from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"73.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Static Physician Global Assessment (sPGA) (0)","description":"The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"43.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Device Operation Failures","description":"Device operation failure (that is, incomplete dose administration) was defined as an event during the treatment period (week 0 to week 12) when the participant indicated that a complete dose of ixekizumab was not delivered and/or the drug delivery device did not perform as expected per the directions for use.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Ixekizumab Antibodies","description":"The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at anytime post-baseline were summarized by drug delivery device group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \\* 100%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]}]},{"type":"SECONDARY","title":"SQAAQ Item Scores: Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)","description":"The SQAAQ is a self-administered questionnaire which provides an assessment of ease of use and confidence with using a device to administer a subcutaneous injection of drug. Participants and injection assistants responded to questionnaire items using a 7-point Likert scale (from \"Strongly Disagree\" to \"Strongly Agree\"). 1 represents \"Strongly Disagree\" while 7 represents \"Strongly Agree\". The ease of use and confidence of ixekizumab subcutaneous administrations across drug delivery device groups were evaluated by SQAAQ item scores at each post baseline visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.67"},{"groupId":"OG001","value":"6.7","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.81"},{"groupId":"OG001","value":"6.8","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.70"},{"groupId":"OG001","value":"6.6","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.76"},{"groupId":"OG001","value":"6.7","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.53"},{"groupId":"OG001","value":"6.7","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.54"},{"groupId":"OG001","value":"6.7","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.79"},{"groupId":"OG001","value":"6.6","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"0.56"},{"groupId":"OG001","value":"6.7","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.70"},{"groupId":"OG001","value":"6.7","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.81"},{"groupId":"OG001","value":"6.6","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.62"},{"groupId":"OG001","value":"6.7","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"0.44"},{"groupId":"OG001","value":"6.8","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.63"},{"groupId":"OG001","value":"6.8","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.67"},{"groupId":"OG001","value":"6.8","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.67"},{"groupId":"OG001","value":"6.7","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"0.80"},{"groupId":"OG001","value":"6.8","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.52"},{"groupId":"OG001","value":"6.8","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.62"},{"groupId":"OG001","value":"6.8","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.75"},{"groupId":"OG001","value":"6.7","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.63"},{"groupId":"OG001","value":"6.8","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.76"},{"groupId":"OG001","value":"6.8","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.81"},{"groupId":"OG001","value":"6.6","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.77"},{"groupId":"OG001","value":"6.8","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.47"},{"groupId":"OG001","value":"6.8","spread":"0.70"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":102},"commonTop":["Upper respiratory tract infection","Injection site reaction"]}}}